Defence Therapeutics Inc
Defence Therapeutics Inc. develops a biological drug enhancer platform that improves the efficacy and safety of a multitude of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on the research, development, and advancement of products using its Accum technology, including antibody drug conjugates targeting vario… Read more
Defence Therapeutics Inc (DTCFF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.512x
Based on the latest financial reports, Defence Therapeutics Inc (DTCFF) has a cash flow conversion efficiency ratio of 0.512x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-720.66K) by net assets ($-1.41 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Defence Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Defence Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Defence Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Defence Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MOBILE FACTORY INC
F:2MF
|
N/A |
|
Korea Computer Inc
KQ:054040
|
-0.007x |
|
HBR Realty Empreendimentos Imobiliários S.A
SA:HBRE3
|
0.080x |
|
GREAT ELM GROUP NEW-001
F:PNC
|
N/A |
|
brooqLy Inc.
PINK:BRQL
|
0.397x |
|
Paragon Union Bhd
KLSE:9407
|
0.030x |
|
Lakeside Holding Limited Common Stock
NASDAQ:LSH
|
-0.037x |
|
Level Biotechnology
TWO:3118
|
0.021x |
Annual Cash Flow Conversion Efficiency for Defence Therapeutics Inc (2020–2024)
The table below shows the annual cash flow conversion efficiency of Defence Therapeutics Inc from 2020 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-06-30 | $-3.58 Million | $-4.29 Million | 1.196x | +128.75% |
| 2023-06-30 | $1.57 Million | $-6.52 Million | -4.162x | -126.69% |
| 2022-06-30 | $-387.56K | $-6.04 Million | 15.596x | +3837.50% |
| 2021-06-30 | $5.49 Million | $-2.29 Million | -0.417x | -485.46% |
| 2020-06-30 | $1.86 Million | $-132.83K | -0.071x | -- |